Home About us Contact
|
Home About us Contact | ||
|
|
||
Monetary Benefits (monetary + benefit)
Selected AbstractsA Comprehensive Analysis of Permission MarketingJOURNAL OF COMPUTER-MEDIATED COMMUNICATION, Issue 2 2001Sandeep Krishnamurthy Godin (1999) has proposed a new idea-permission marketing. Here, consumers provide marketers with the permission to send them certain types of promotional messages. This is seen as reducing clutter and search costs for the consumer while improving targeting precision for marketers. This paper makes three contributions: First, a critical analysis of the concept and its relationship to existing ideas in the marketing literature is discussed. Second, a taxonomy of four models used to implement permission marketing today, direct relationship maintenance, permission partnership, ad market and permission pool, is presented. Permission intensity is seen as a key differentiator among models. Finally, a comprehensive conceptual cost-benefit framework is presented that captures the consumer experience in permission marketing programs. Consumer interest is seen as the key dependent variable that influences the degree of participation. Consumer interest is positively affected by message relevance and monetary benefit and negatively affected by information entry/modification costs, message processing costs and privacy costs. Based on this framework, several empirically testable propositions are identified. [source] Cost,benefit analysis of team supervision: the development of an innovative model and its application as a case study in one Finnish university hospitalJOURNAL OF NURSING MANAGEMENT, Issue 5 2001Kristiina Hyrkäs Lic. Aim To develop a model of costs and benefits of team supervision and a formula, which are examined more closely by means of an example. Background The popularity of clinical supervision (CS) as one of the methods of supporting health care practitioners' professional development (formative function), coping (restorative function) and quality improvement (normative function) has increased in the 1990s. CS may take the form of one-to-one or group supervision. Team supervision is a special form of group supervision. It means a group that has an interrelated work life outside the group. A host of literature and articles is available on CS. However, the costs and benefits of CS are less examined even though these have given rise to discussion particularly among decision-makers, because the monetary benefit of CS remains unsolved. Method A nominal group technique was used to develop a model of costs and benefits of team supervision and a formula was derived on the basis of the model. The existing statistical data, for example a hospital ward's annual reports, data on sick days and reports on indemnities were utilized in the application of the formula. Findings and conclusion Team supervision was efficient in economic terms on the example ward. The model and the formula constitute a first attempt to ascertain the net present benefit of team supervision. Both the model and the formula need to be further tested, specified and refined. [source] IS EQUALITY OF OPPORTUNITY POLITICALLY FEASIBLE?ECONOMICS & POLITICS, Issue 1 2005Stefan Zink We develop a political-economy model where the amount of education subsidies is determined in a majority vote and spending is financed by revenues from taxation. Our analysis demonstrates that limiting the extent of subsidization and thus excluding the poor from gaining enough education can be a political equilibrium. Despite being the main beneficiaries of subsidies, the politically decisive middle class hesitates to extend monetary benefits, since improved access to higher education diminishes the return to education. Moreover, a non-monotone relation between inequality and the extent of redistribution through tax-financed educational subsidies obtains. [source] Evaluation of an action threshold-based IPM wheat model in Rheinland (Germany) in 1999/2001,EPPO BULLETIN, Issue 3 2003M. Heger Under the specific agricultural and climatic conditions of Rheinland (DE), 48 field trials in three years demonstrated the practicability of the action threshold-based fungicide strategy of the IPM wheat model. The underlying data for action thresholds and dosage of fungicides applied are outlined. The cereal pathogens concerned, predominantly Mycosphaerella graminicola and Puccinia recondita, were controlled in the early stages of epidemic development using reduced rates of fungicides. The IPM wheat model gave a high efficacy of control, in terms of disease incidence and disease severity, under both low and high disease pressure conditions. The yield levels resulting from this effective reduction in diseases were nearly the same as those of the disease-free variant. Total yield increase varied between 15% and 30% with an overall average of around 20%, and resulted in monetary benefits of 50,100 EUR ha,1 in the years considered. [source] Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progressionHEALTH ECONOMICS, Issue 11 2008Gregory S. Zaric Abstract Limited use conditions (LUCs) are a method of directing treatment with new drugs to those populations where they will be most cost effective. In this paper we investigate how a drug manufacturer could determine pricing and LUCs to maximize profits. We assume that the payer makes formulary decisions on the basis of net monetary benefits, that the disease can be modeled using a Markov model of disease progression, and that the drug reduces the probability of progression between states of the Markov model. LUCs are expressed as a range of probabilities of disease progression over which patients would have access to the new drug. We assume that the manufacturer determines the price and LUCs in order to maximize profits. We show that an explicit trade-off exists between the drug's price and the use conditions, that there is an upper bound on the drug price, that the proportion of the population targeted by the LUC does not depend on quality of life or costs in each health state or the payer's willingness to pay, and that high drug prices do not always correspond with high profits. Copyright © 2008 John Wiley & Sons, Ltd. [source] | ||||||||||